Childhood diseases, 10, 65

Children and minors, 10, 260

appropriate age for testing, 10, 27, 51, 297

carrier screening, 7, 10, 102

see also Newborn screening

Cholesterol, 45, 51, 62, 91

Chorionic villus sampling (CVS), 35, 37, 46, 73, 76-77, 78

Chromosomal abnormalities and analysis, 36, 46, 60, 63, 75, 166

Chromosomal siting, see Gene mapping and linkage

Civilian Health and Medical Program of the Uniformed Services (CHAMPUS), 243

Clinical Chemistry and Toxicology Devices Panel of Experts, 142

Clinical genetics, creation of specialty, 12, 138

Clinical Laboratory Improvement Act of 1967 (CLIA67), 121, 124

Clinical Laboratory Improvement Advisory Council, 143

Clinical Laboratory Improvement Amendments of 1988 (CLIA88), 11,12-13, 124-127, 136, 137, 141, 142, 143, 237, 274

high-complexity classification under, 12, 125-126, 138

research laboratory regulation, 13, 139

Clinical sensitivity, 37, 139

Clinical trials, 26, 131

Cloning, 29, 30, 31

College of American Pathologists (CAP), 121, 122, 291

Colon cancer, 31, 34, 36, 92, 96, 97, 177

Commercial testing services, 2, 10, 13, 27, 48, 50, 107, 117, 127, 134-135

investigational device use, 13, 142

Community-based genetics education, 2, 14, 16-18, 52, 185-198

Complex causation, see Multifactorial disorders

Computer systems for education, 18, 303-304

interactive, 15, 18, 173, 230, 303-304

Confidentiality and disclosure, 2, 3, 10, 14, 21, 22-24, 52, 53, 151, 157, 172, 247, 250-252, 264-273, 279-280;

see also DNA data and data banking

mental disorders predictive testing, 9-10, 106

misattributed paternity, 6, 23, 100, 127, 163, 175

necessary breaches, 15-16, 22, 23, 53, 165-166, 172, 255, 264-267

sickle cell screening programs, 41

Confirmatory testing

for investigational devices, 131-132

newborn screening, 5, 65-66, 99

for prenatal screening, 36, 80, 103-104

Conflicts of interest, 22, 48-49

Congenital hypothyroidism

screening programs, 5, 66, 68-69

Consent, see Informed consent

"Consumer's Guide to Genetic Testing," 18, 198

Continuing education programs, 20, 220, 223, 228-229

Contraception, 71

Conventional therapies, 29

Coronary artery disease, 1, 34, 51, 62, 91

predictive tests, 9, 94-95

Cost-benefit analysis, 53, 153, 304

Cost-effectiveness analysis, 15, 28, 53, 153, 304-305

Costs of screening and testing, 4, 20, 47-48, 132-133, 142, 235

neonatal, 6, 100

and quality assurance programs, 123-124, 133

Council of Regional Networks for Genetic Services (CORN), 120-121, 127, 211, 215, 244, 291

Council on Resident Education in Obstetrics and Gynecology (CREOG), 218, 219, 221-222, 228

Counseling and client education, 1, 4, 10, 12, 14-16, 23, 65, 74, 146-178, 300, 302

carrier testing, 7, 101, 102, 163-166, 175-176

Front Matter (R1-R14)

Exective Summary (1-28)

1 Setting the Stage (29-58)

2 Genetic Testing and Assessment (59-115)

3 Laboratory Issues in Human Genetics (116-145)

4 Issues in Genetic Counseling (146-184)

5 Public Education in Genetics (185-201)

6 Personnel Issues in Human Genetics (202-233)

7 Financing of Genetic Testing and Screening Services (234-246)

8 Social, Legal, and Ethical Implications of Genetic Testing (247-289)

9 Research and Policy Agenda (290-308)

Appendix A: Workshop Participants (309-316)

Appendix B: Committee Biographies (317-324)

Index (325-338)